Skip to main content
Advertising

Originally published February 22, 2013 at 2:02 AM | Page modified February 22, 2013 at 7:02 AM

  • Share:
           
  • Comments (0)
  • Print

Blaze Bioscience raises $8.5M

The Seattle company’s Tumor Paint technology attaches a fluorescing “beacon” to a molecule that targets solid tumors, with the goal of highlighting cancer cells so they can be completely removed.

By Seattle Times business staff

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

Blaze Bioscience, a Seattle biotechnology company, said it has completed an $8.5 million financing and will use the money for early clinical trials of a product for visualizing cancer tumors during surgery.

The company’s Tumor Paint technology attaches a fluorescing “beacon” to a molecule that targets solid tumors; the goal is to highlight cancer cells so they can be completely removed.

Blaze, a spin-off using discoveries at the Fred Hutchinson Cancer Research Center, has now attracted $9.8 million since its founding in 2010.

News where, when and how you want it

Email Icon


Advertising